These findings suggest a potential role for PD-1 and/or BTK inhibitor-based combination therapies in the management of DLBCL-type RT, emphasizing the need for further research to optimize these approaches for improved clinical outcomes. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.